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In a randomised phase 3 trial, panitumumab significantly improved progression-free survival (PFS) in patients with refractory
metastatic colorectal cancer (mCRC). This analysis characterises the association of PFS with CRC symptoms, health-related quality of
life (HRQoL), and overall survival (OS). CRC symptoms (NCCN/FACT CRC symptom index, FCSI) and HRQoL (EQ-5D) were
assessed for 207 panitumumab patients and 184 best supportive care (BSC) patients who had at least one post-baseline patient-
reported outcome (PRO) assessment. Patients alive at week 8 were included in the PRO and OS analyses and categorised by their
week 8 progression status as follows: no progressive disease (no PD; best response of at least stable disease) vs progressive disease
(PD). Standard imputation methods were used to assign missing values. Significantly more patients were progression free at weeks
8–24 with panitumumab vs BSC. After excluding responders, a significant difference in PFS remained favouring panitumumab
(HR¼0.63, 95% CI¼0.52–0.77; Po0.0001). At week 8, lack of disease progression was associated with significantly and clinically
meaningful lower CRC symptomatology for both treatment groups and higher HRQoL for panitumumab patients only. Overall
survival favoured no PD patients vs PD patients alive at week 8. Lack of disease progression was associated with better symptom
control, HRQoL, and OS.
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Colorectal cancer (CRC) is the third most common cancer
worldwide, with more than one million new diagnoses each year,
and more than 500000 deaths annually (Parkin et al, 2005).
Despite advancements in treatment for this disease which include
cytotoxic agents and targeted therapies, most patients eventually
progress, become symptomatic, and succumb to their disease (de
Gramont et al, 2000; Douillard et al, 2000; Saltz et al, 2000;
Rothenberg et al, 2003; Cunningham et al, 2004; Hurwitz et al,
2004; Saltz et al, 2004; Tournigand et al, 2004).
Progression-free survival (PFS) has been shown to correlate with
overall survival (OS) in the first-line setting for metastatic
colorectal cancer (mCRC) (Tournigand et al, 2004). Since disease
progression is a consequence of tumour growth, and it is often
associated with symptomatic progression, using PFS as a surrogate
end point in CRC trials is also likely to predict clinical benefit in
the setting of refractory disease. However, the role of PFS as a
predictor of OS in later lines of treatment for mCRC has not yet
been demonstrated.
In mCRC, monoclonal antibodies that target the epidermal
growth factor receptor (EGFR) have demonstrated efficacy
(Cunningham et al, 2004; Van Cutsem et al, 2007a,b). Currently,
two anti-EGFR antibodies are approved for the treatment of
mCRC, panitumumab and cetuximab (Yang et al, 1999; Yarden
and Sliwkowski, 2001; Foon et al, 2004). Panitumumab is a fully
human monoclonal antibody that inhibits ligand binding (e.g.,
EGF and TGF-a) and associated cellular processes that lead
to tumour growth, cell survival, and metastases. A phase 3
randomised-controlled trial of panitumumab plus best supportive
care (BSC) vs BSC alone in patients with mCRC who had
progressed after standard therapy demonstrated that panitumu-
mab plus BSC was well tolerated and significantly improved PFS
(Van Cutsem et al, 2007a).
The clinical benefit of delaying tumour progression (i.e., PFS)
was not fully explored in the primary analysis of this study. From
the primary analysis of patient-reported outcomes (PROs), no
significant differences in CRC symptoms and health-related quality
of life (HRQoL) were seen between the two treatment groups
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s(Van Cutsem et al, 2007a). Potential HRQoL and CRC symptom
benefits associated with panitumumab therapy are important
aspects of clinical benefit, particularly in a chemorefractory
population with progressing disease. In addition, OS is a
recognised standard end point in this setting. In this report,
exploratory analyses were conducted that assessed the association
between PFS and patient-reported CRC symptoms and HRQoL, as
well as OS.
PATIENTS AND METHODS
Patients and study design
This phase 3 multicentre, open-label randomised-controlled trial
evaluated the efficacy and safety of panitumumab plus BSC
(panitumumab) compared with BSC alone (BSC) given every 2
weeks in patients with mCRC that had progressed on prior
fluoropyrimidine, irinotecan, and oxaliplatin (Figure 1) (Van
Cutsem et al, 2007a). Relevant inclusion criteria were pathologic
diagnosis of metastatic colorectal adenocarcinoma, radiologic
documentation of disease progression during or within 6 months
following the last administration of fluoropyrimidine, irinotecan,
and oxaliplatin, prior exposure to prespecified doses of irinotecan
and oxaliplatin, and two or three prior chemotherapy regimens.
Both criteria of disease progression and dose intensity were
retrospectively centrally confirmed. Additional details of the study
design and key eligibility criteria are reported in the primary
publication (Van Cutsem et al, 2007a).
Objective tumour response was assessed by central radiology
review using modified RECIST criteria (Therasse et al, 2000) at
specified time points from weeks 8 to 48, and every 3 months
thereafter until disease progression. Responses were confirmed not
less than 4 weeks after response criteria were first met. Tumour
response, including stable disease, was evaluated at the first
scheduled assessment (week 8). At the discretion of the
investigator, patients could be evaluated for radiographic tumour
assessment after developing symptoms consistent with disease
progression. Best supportive care patients determined by investi-
gator to have disease progression were allowed to receive
panitumumab under a separate cross-over study (Van Cutsem
et al, 2007a,b).
HRQoL and CRC symptomatology assessments
Patient-reported outcome assessments were taken at baseline,
every 2 weeks or monthly during the treatment phase of the study,
and at the 30-day safety follow-up visit (Table 1). CRC
symptomatology was measured using the NCCN FACT Colorectal
Symptom Index (FCSI) and HRQoL was measured using the
EQ-5D Health Index Scale, the EQ Visual Analog Scale (VAS), and
two global health items from the Global Quality of Life Scale of the
European Organizations for the Research and Treatment of Cancer
Quality of Life Questionnaire – Core (EORTC QLQ-C30).
The FCSI was derived as a set of brief, clinically relevant CRC
symptoms for assessing symptomatic response. It comprises of the
most important symptoms associated with CRC including pain,
energy, diarrhoea, nausea, stomach swelling or cramps, appetite,
and weight loss, and more general aspects of HRQoL such as
ability to enjoy life and contentedness with QoL (Cella et al, 2003).
The nine-item FCSI is scored to produce a total score. Linear
transformation was used to standardise the raw score, so that the
total score ranges from 0 (severely symptomatic on all symptoms
assessed) to 100 (symptom-free on all symptoms assessed). For the
FCSI, the minimal clinical important difference (MCID) was
defined as a change in score of 4 points or more (in a scale of
0–100) (Mathias et al, 2006). The FCSI was specifically developed
to be used in CRC research and designed to be sensitive to
symptomatic progression as experienced by patients with meta-
static disease (Cella et al, 2003). The relevance of these specific
symptoms also correlates well with routine clinical observations of
those engaged in the care of these patients.
The EQ-5D Health Index Scale provides a preference-weighted
assessment of overall QoL across five dimensions that include
mobility, self-care, usual activity, pain or discomfort, and anxiety
or depression. Each dimension has three possible outcomes (no
problems, moderate problems, and extreme problems), with a total
score ranging from 0 corresponding with death to 1 corresponding
with perfect health (Walters and Brazier, 2005). Estimates for the
MCID for the EQ-5D Index include a change in score of 0.074
points (Osoba et al, 1998) and 0.08 points or more (Osoba et al,
1998; Mathias et al, 2006).
The EQ-5D Visual Analog Scale (VAS) provides an assessment
of current health status on a vertical scale and ranges from 0 to 100
with 0 representing worst imaginable health state and 100
representing best imaginable health state (Brooks et al, 2003).
For the EQ-5D VAS, the MCID was defined as a change in score
of 5.48 points or more (Mathias et al, 2006).
The EORTC QLQ-C30 is a validated HRQoL 30-item instrument
(Aaronson et al, 1993). In this study, the Global Health Status/QoL
Scale of the EORTC QLQ-C30 was used. It consists of two items
measuring overall health status and overall QoL. Linear transfor-
mation is used to standardise the raw score into a scale ranging
from 0 to 100 with higher scores indicating better overall QoL
(Fayers et al, 1995). For the Global Health Status/QoL Scale, the
MCID was defined as a change in score of 7.07 points or more
(Mathias et al, 2006).
Statistical analysis
The primary study end point was PFS by blinded central radiology
assessment. The primary analysis of PFS included tumour
assessments after crossover to panitumumab for BSC patients if
disease progression was not centrally confirmed while the patient
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Figure 1 Phase 3 study schema.
Table 1 PRO assessment and schedule
PRO instrument Assessment schedule
FACT-FCSI Baseline, every 2 weeks during
treatment, and at the 30-day safety
follow-up visit
EUROQOL (EQ-5D) Health Index Baseline, monthly during treatment, and
at the 30-day safety follow-up visit
EUROQOL (EQ-5D) Visual Analog
Scale (VAS)
EORTC QLQ-C30 Global Health
Status/QoL Scale
Patient-reported outcomes with panitumumab
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response by blinded central review (prespecified for testing), OS,
and PROs as described above. To assess whether the treatment
differences in PFS were due to patients with an objective response,
a post-hoc sensitivity analysis of PFS that removed responding
patients in the panitumumab group (i.e., patients with a best
response of at least partial response) was conducted to evaluate the
contribution of non-responding patients on the treatment effect
with panitumumab. Statistical analyses for the primary and
secondary end points have been described previously (Van Cutsem
et al, 2007a,b).
The objective of the analyses presented herein was to evaluate
the association between delaying tumour progression (i.e., PFS)
and CRC symptoms, HRQoL, and OS. For PRO analyses (i.e., CRC
symptoms and HRQoL), patients were included if they had at least
one post-baseline PRO assessment (the PRO all enrolled analysis
set). Additionally, to help reduce bias, patients who died prior to
week 8 were excluded from the PRO analysis. Patients were
categorised into one of two groups based on progression status as
of week 8 as follows: (1) patients who were progression free (i.e.,
had a best confirmed response of at least stable disease); or (2)
patients with tumour progression (i.e., had less than stable
disease).
t-Tests and least-squares estimates were calculated for differ-
ences in PRO measures at weeks 4, 8, 12, and 16 controlling for
baseline score by progression status as of week 8 (no tumour
progression vs tumour progression) within each treatment arm.
For each treatment group, descriptive statistics of point estimates
of scores over time for all instruments and of the difference in
scores between the two tumour progression groups over time for
all instruments were summarised.
Missing PRO data were imputed using the following two
methods: last value carried forward (LVCF) method and a slope
method (Fairclough, 2002; Fielding et al, 2006). For the LVCF
method, missing observations were replaced with the last observed
value carried forward for reasons other than death or zero value
carried forward at death. Additional rules for the LVCF method
were as follows: (1) patients missing values in between two
observed values had the earlier observed value carried forward
unless the subsequent observed value occurred after disease
progression, in which case the later observed value was carried
backward; and (2) if the baseline data were missing then the
missing data were imputed using the first observation carried
backwards.
The slope method applied forward linear interpolation of
observed data to impute missing data. Time was measured relative
to randomisation with observed data assigned to the day it was
obtained, and the day of a missed assessment is assigned to the day
the assessment was scheduled per protocol. The predicted value
from a linear regression of observed data prior to a missed
assessment was used to impute a value at the time of the missed
assessment. Prior imputed values were not used to impute
subsequent values. If there was only one observed value prior to
a missed assessment, then the last value was carried forward to the
missed assessment. If the first scheduled assessment was missing,
then it was not imputed.
For OS, within each treatment group, survival was examined
among patients surviving to at least week 8 according to their
progression status as of week 8. A Cox regression model was used
to examine the correlation between time to radiologic progression
(TTP) and time to death (TTD) among all patients. Time to
radiologic progression was defined as the time from randomisation
to radiologic disease progression per modified-RECIST by blinded
central review. Patients who died without radiologic progression
were censored at their last radiologic assessment of TTP. The
model included indicators for the randomisation factors (ECOG
performance score and geographic region) and a time-dependent
covariate for radiologic progressive disease (PD).
RESULTS
Demographics
In this phase 3 trial, 463 patients were randomised, 231 patients to
panitumumab and 232 patients to BSC (Van Cutsem et al, 2007a).
Median follow-up time for survival (enrollment to data cutoff for
analysis) for all patients was 72 weeks (range¼52–113). In the
BSC group, 176 (76%) patients received panitumumab under the
crossover study (Van Cutsem et al, 2007b).
In the all randomised analysis set, 22 (10%) of panitumumab
patients had a partial response and 62 (27%) patients had stable
disease. Of the BSC patients, no patients had an objective response
and 23 (10%) patients had stable disease. Disease control (the sum
of objective response and stable disease rates) was seen in 84 (36%)
panitumumab patients and 23 (10%) BSC patients.
For the PRO analyses, 207 (90%) panitumumab patients and 184
(79%) BSC patients had at least one post-baseline PRO assessment
and comprised the PRO All Enrolled analysis set (Table 2). As
expected from the higher rate of discontinuation because of
disease progression in the BSC group, a higher percentage of
panitumumab patients had evaluable PRO data compared with the
BSC group from week 4 onwards. At week 4, EQ-5D data were
available for 91% of panitumumab patients and 70% of BSC
patients; by week 16, data were available for 30% and 4% of
patients, respectively. The proportion of patients with available
data for the FCSI at weeks 4 and 16 for each treatment group were
similar as that for the EQ-5D at those respective time points.
Contribution of stable disease on PFS
To evaluate the importance of achieving stable disease in this
population, an analysis was conducted where panitumumab
patients who had an objective response were excluded from the
primary analysis of PFS (all randomised patients, panitumumab vs
BSC). A significant difference in PFS remained for panitumumab
over BSC (hazard ratio¼0.63, 95% CI¼0.52–0.77; Po0.0001)
(Figure 2). These data indicated that improvement in PFS was not
derived solely from the subset of patients with a best response of
partial response. Indeed, 80% of the overall treatment effect could
be accounted for by panitumumab patients without an objective
response, specifically by patients with stable disease.
Table 2 Patient analysis sets and PRO data availability
Panitumumab
plus BSC BSC alone
Total randomised (n) 231 232
PRO all enrolled analysis set (n) 207 184
PRO all enrolled analysis set and alive at week 8,
EQ-5D (n)
179 164
Patients completing EQ-5D (n)
Week 4 189 129
Week 8 111 47
Week 12 91 14
Week 16 62 7
PRO all enrolled analysis set and alive at week 8,
FCSI (n)
181 166
Patients completing FCSI subscale (n)
Week 4 190 130
Week 8 112 48
Week 12 90 14
Week 16 62 7
Patient-reported outcomes with panitumumab
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sAssociation between PFS and disease-related symptoms
and HRQoL
Patient-reported outcomes were evaluated in each treatment group
for patients alive at week 8 and stratified by tumour progression
status as of week 8. For both the FCSI and EQ-5D Health Index,
among panitumumab patients, those who were progression free at
week 8 maintained mean scores throughout treatment while those
with tumour progression at week 8 had a steady decline in the
mean scores throughout treatment (data not shown).
The difference in the FCSI scores between patients who were
progression free (no PD) and those with progression (PD) at week
8 was evaluated in both treatment groups (Figure 3). For both
panitumumab or BSC groups, achieving at least stable disease at
week 8 (i.e., being progression free) was associated with significant
and clinically meaningful improvement in control of disease-
related symptoms at all time points (weeks 4, 8, 12, and 16)
(Figure 3). The lower limits of the 95% confidence intervals
excluded 0 (i.e., statistical significance) and the point estimates
exceeded the MCID of  4 points (i.e., clinically meaningful) at all
time points for the panitumumab group and at weeks 8 to 16 for
the BSC group.
For the EQ-5D Health Index, the difference in scores for
panitumumab patients alive at week 8 who did not have tumour
*Panitumumab (all) and BSC curves are from the primary analysis for PFS (Van Cutsem et al, 2007).
**For panitumumab (w/o PR): BSC group; adjusted for ECOG and region. Pmab=panitumumab  
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Figure 2 Sensitivity analysis of progression-free survival (PFS) with and without responders in the panitumumab group.
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Figure 3 Mean FACT-FCSI difference (95% CI) in scores by progression
status at week 8 (central review, patient-reported outcome (PRO) all
enrolled, landmark analysis).
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clinically meaningful at all time points (Figure 4). For BSC
patients, the difference in scores between the tumour progression
groups was not significant or clinically meaningful (Figure 4). Lack
of disease progression with panitumumab for patients alive at
week 8 was associated with better HRQoL.
Results for the FCSI and EQ-5D for all treatment groups were
similar regardless of imputation method. Additionally, similar
results for panitumumab and BSC patients stratified by tumour
progression status were observed for the EQ-5D VAS and EORTC
Global Scale (data not shown).
Association of tumour progression status on OS in the
panitumumab patients
Panitumumab patients who were alive at week 8 without PD had a
median TTD of 7.6 months (Figure 5). For panitumumab patients
alive with a PD at week 8, the median TTD was 3.6 months. For
BSC patients who were alive at week 8, those without PD had a
median TTD of 8.6 months vs those with PD who had a median
TTD of 4.3 months (data not shown).
DISCUSSION
This exploratory analysis was conducted to evaluate the associa-
tion of tumour progression status with HRQoL. Here, we first
evaluated the contribution of stable disease on the overall effect of
panitumumab on PFS. These analyses revealed that 80% of the
treatment effect of panitumumab on PFS was retained after
removing patients that responded to the drug. These results
indicate that the treatment benefit with panitumumab is obtained
in patients with disease stabilisation. These results are of interest
given that patients in this trial had disease progression after
exposure to adequate chemotherapy dose intensity that was
adjudicated independently.
It is hypothesised that panitumumab induced clinical benefit by
halting disease progression. A similar effect has been observed for
other targeted compounds used in monotherapy (Ratain et al,
2006; Escudier et al, 2007). Therefore, we then evaluated the
association of PFS and clinical outcomes in patients with mCRC
refractory to standard chemotherapy regimens. There was a
significant and clinically meaningful association between being
progression free and better HRQoL, CRC symptomatology, and OS
in panitumumab patients. An association between improved PFS
and favourable OS prognosis was also observed in the BSC
arm, potentially reflecting a subpopulation with more indolent
disease. However, compared to BSC alone, treatment with
panitumumab resulted in approximately 20% more patients who
were progression free at weeks 8, 12, and 16 (Van Cutsem et al,
2007a,b). Although more patients were rendered progression free
with panitumumab compared to BSC, and being progression free
was associated with a favourable OS prognosis, these progression-
free rate differences did not translate into differences in OS when
all patients were compared (Van Cutsem et al, 2007a,b), possibly
due to the effect of early crossover of patients in the BSC to
panitumumab treatment. Indeed, 76% of patients in the BSC arm
crossed over to receive panitumumab at a median time of 7.0
weeks. In these patients, panitumumab treatment was associated
with similar clinical activity as that in the phase 3 study (Van
Cutsem et al, 2007a,b).
The reasons underlying the association between progression
status and HRQoL in the panitumumab arm may relate to the
overall effects of panitumumab on tumour growth arrest. Although
objective responses were observed in 10% of patients, a larger
number of patients within the stable disease population also had
reductions in tumour burden. Indeed, in panitumumab patients
with stable disease, there was a median decrease in maximum
target lesion size of approximately 12% compared to baseline,
whereas BSC patients with stable disease had a median increase of
approximately 7% (Amgen, data on file). Overall, the majority of
patients achieving a best response of at least stable disease in the
panitumumab group had a reduction in tumour volume, which
was associated with symptom improvement.
Missing data for QoL end points was largely due to disease
progression (and therefore QoL data collection halted) in this
advanced-stage population, especially among the BSC patients, 70%
of whom had disease progression by week 8 (and subsequently
crossed over to panitumumab therapy in the extension trial). By
using either of the two imputation methods, LVCF and slope, the
true effect on the PROs by treatment may have been under-
estimated. With the LVCF method, imputation of data halts
progression at dropout or crossover and carries forward the pre-
dropout assessment throughout the study, with zero carried forward
at death. This method may bias the results in favour of a treatment
that results in more dropouts associated with morbidity. In this case
it can result in bias by imputing potentially higher scores in the BSC
patient than the panitumumab patients. In some settings, the slope
method may be more conservative and less biased towards either
treatment group, and imputation of a score of zero at death with the
LVCF method may be biased against groups with high death rates.
These limitations do not seem to have affected the overall findings
as results were consistent across imputation methods. However,
these imputation methods ignore the effect of panitumumab
received after crossover on QoL measures, as these end points were
not measured in the crossover extension trial.
These results further suggest that halting disease progression is
associated with clinical benefit of sustained or improved QoL and
prolonged survival in patients with chemorefractory mCRC. This
hypothesis should be tested prospectively in randomised-controlled
trials. Further studies are ongoing to evaluate the benefits of
panitumumab in subsets of patients with different molecular
characteristics of resistance or sensitivity to this targeted therapeutic
agent (Moroni et al, 2005; Lievre et al, 2006; Benvenuti et al, 2007;
Sartore-Bianchi et al, 2007) as well as in earlier lines of therapy.
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